Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Radiolabelled chemotherapeutics.

S Rottey¹, A Signore, C Van de Wiele

¹Division of Medical Oncology, Gent University Hospital, Gent, Belgium.

The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of

|April 11, 2007

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma.

ESMO open·2025

Same author

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Clinical pharmacology and pharmaceutical medicine - creation of a new specialist title for physicians in Belgium.

Acta clinica Belgica·2025

Same author

First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Same author

Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial.

ESMO open·2023

Same author

Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future.

ESMO open·2022

Same journal

Evidence-based data on PET in infectious and inflammatory diseases.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2026

Same journal

Evidence-based PET in cardiovascular infectious diseases: an umbrella review.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2026

Same journal

Evidence-based role of PET imaging in cardiac and systemic sarcoidosis: an umbrella review of the current literature.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2026

Same journal

Response assessment in [177Lu]PSMA: where do we stand?

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2026

Same journal

FDG PET/CT imaging in recurrent papillary thyroid cancer: does BRAF mutation status matter?

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2026

Same journal

Radionuclide lung scintigraphy in the evaluation of suspected acute and chronic pulmonary embolism: methods, interpretation, and lexicon. A basic user guide for the clinician.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2026

See all related articles

Radiolabeled chemotherapeutics aid understanding of drug action and metabolism. Imaging techniques like positron emission tomography (PET) and single photon emission computed tomography (SPECT) show limited predictive value for therapy response in combination treatments.

Area of Science:

Nuclear medicine
Oncology
Pharmacology

Background:

Chemotherapeutics are crucial in cancer treatment.
Radiolabeling enables advanced imaging of drug behavior.
Understanding drug biodistribution and metabolism is key to optimizing therapy.

Purpose of the Study:

To review the role of radiolabeled chemotherapeutics in imaging.
To assess the utility of these agents in understanding drug mechanisms and metabolism.
To evaluate their potential as predictors of treatment response.

Main Methods:

Review of studies involving radiolabeled chemotherapeutics for PET and SPECT imaging.
Analysis of data on biodistribution, metabolism, and tumor uptake.
Correlation of imaging findings with patient treatment outcomes.

Related Experiment Videos

Main Results:

Radiolabeled chemotherapeutics provide insights into drug action and metabolic pathways.
Imaging helps explain treatment failure or the efficacy of biomodulating agents.
Predictive utility for treatment response is limited to monotherapy regimens.

Conclusions:

PET and SPECT imaging with radiolabeled chemotherapeutics enhance understanding of drug behavior in humans.
These imaging modalities offer rationale for treatment outcomes.
Their role in predicting therapy response is restricted to monotherapy.